| Speakers from |
 |
|
Abbott
Amgen
AstraZeneca
Bayer Healthcare
Bio-Modeling Systems
Definiens AG
EMEA
F. Hoffmann-La Roche
GlaxoSmithKline
Ingenuity Systems
Innsbruck University
Institute for Women’s Health, UCL
Johnson & Johnson
Lundbeck
Merck
Millipore
National Institute of Standards & Technology
NeuroSearch
Novartis
Olink Bioscience
Pfizer
Rules Based Medicine
Ryerson University
Schering-Plough
The Critical Path Institute
The Institute of Cancer Research
UCB Group
University College Dublin
Uppsala University
|
|
|
|
|
| Featured Speakers |
|
|
|
Anders Alderborn,
Associate Professor, Medical Genetics, Uppsala University
|
 |
|
|
Stewart Bates,
Director Stevenage Core Technologies Group, Discovery Technology Group, GlaxoSmithKline
|
|
|
|
Maria Bobadilla,
Biomarker Expert Metabolic and Vascular Disease, F.Hoffman-La Roche
|
|
|
|
Adam S. Corner,
Senior Scientist, Europe, Ingenuity Systems
|
|
|
|
Maryellen de Mars,
Director Clinical Biomarkers, The Critical Path Institute
|
|
|
|
Viswanath Devanarayan,
Director, Global Exploratory Stats, Global Stats & Data Management, Abbott
|
|
|
|
Dominic Eisinger,
Director of Strategic Development, Rules Based Medicine
|
|
|
|
Bruno Flamion,
Chairman, EMEA Scientific Advice Working Party, Federal Agency for Medicinal and Health Products, Belgium
|
|
|
|
Dorothee Foernzler,
Biomarker - Experimental Medicine Leader, F. Hoffmann-La Roche
|
|
|
|
Scott Fogerty,
Clinical Development Manager, Affymetrix Inc
|
|
|
|
Simon Fredriksson,
Chief Scientific Officer, Olink Bioscience
|
|
|
|
William Gallagher,
Associate Professor, University College Dublin
|
|
|
|
Alasdair Gaw,
Director of Discovery Medicine for Respiratory and Inflammation, Astrazeneca
|
|
|
|
Peter Groenen,
Director Pharmacogenetics, Schering Plough
|
|
|
|
Brett Hall,
Team Lead Biomarkers, Ortho Biotech Oncology R&D, Janssen Pharmaceutica
|
|
|
|
Thomas Herget,
Senior Director PC-R-New Technology Evaulation Performance & Life Science Chemicals, Merck KGaA
|
|
|
|
Philip Hewitt,
Head of Molecular Toxicology, Merck Serono Research
|
|
|
|
Darren Hodgson,
Biomics Advisor Oncology Therapy Area, AstraZeneca
|
|
|
|
Francois Iris,
Founder, Chairman & CSO, Bio-Modeling Systems
|
|
|
|
Ian James,
Director Diagnostics Europe, Molecular Medicine, Pfizer
|
|
|
|
Mark Jones,
Associate Director Molecular Biomarkers, UCB Group
|
|
|
|
Rose Maciewicz,
Chief Scientist Respiratory & Inflammation Research Area, AstraZeneca
|
|
|
|
John Marshall,
Association Professor of Biology and Chemistry, Ryerson University
|
|
|
|
Wolfgang Meyer-Sabellek,
Senior Medical Advisor AstraZeneca
|
|
|
|
Jens D. Mikkelsen,
Professor, Scientific Director Head of Translational Neurobiology NeuroSearch
|
|
|
|
James Milligan,
Safety Science Expert, Global Patient Safety Physician, AstraZeneca
|
|
|
|
Josef Ozer,
Senior Principal Scientist, Biomarker Lead, Pharmacokinetics, Dynamics, and Metabolism, Pfizer
|
|
|
|
Harsukh Parmar,
Director, Global Discovery Medicine, Respiratory & Inflammation Therapy Area, AstraZeneca
|
|
|
|
Simon Read,
Lead Biomarker and Experimental Medicine, F.Hoffman-La Roche
|
|
|
|
Chris Russell,
Director, Medical Sciences, Amgen
|
|
|
|
Ina Schuppe Koistinen,
Principal Scientist Molecular Toxicology/Safety Assessment, AstraZeneca
|
|
|
|
Martin Smith,
Sales Manager Northern Europe, Life Sciences Solutions, Definiens AG
|
|
|
|
Daniel Stein,
Head of Infectious Disease Profiling, Novartis
|
|
|
|
Linda Surh,
Director, CEDD Global Regulatory Affairs, Neurosciences and Pharmacogenetics, GlaxoSmithKline
|
|
|
|
John Timms,
Head of Cancer Proteomics Laboratory, Institute for Women's Health, UCL
|
|
|
|
Alan Tunnicliffe,
European Technology Manager, Millipore Bioscience Division
|
|
|
|
Alain van Gool,
Head Molecular Profiling, Translational Medicine Research Centre Singapore, Schering Plough
|
|
|
|
Heinz Zwierzina,
Professor of Internal Medicine/Medical Oncology, Innsbruck University
|
|
|
|
|
|
